These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 39064468)

  • 21. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
    Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural insights into somatostatin receptor 5 bound with cyclic peptides.
    Li YG; Meng XY; Yang X; Ling SL; Shi P; Tian CL; Yang F
    Acta Pharmacol Sin; 2024 Nov; 45(11):2432-2440. PubMed ID: 38926478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distribution and functional significance of somatostatin receptors in malignant melanoma.
    Lum SS; Fletcher WS; O'Dorisio MS; Nance RW; Pommier RF; Caprara M
    World J Surg; 2001 Apr; 25(4):407-12. PubMed ID: 11344389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated miR-16-5p induces somatostatin receptor 2 expression in neuroendocrine tumor cells.
    Jo H; Park Y; Kim J; Kwon H; Kim T; Lee J; Pyun JC; Lee M; Yun M
    PLoS One; 2020; 15(10):e0240107. PubMed ID: 33045023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.
    Samson SL
    Neuroendocrinology; 2015; 102(1-2):8-17. PubMed ID: 25792118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.
    Li SC; Martijn C; Cui T; Essaghir A; Luque RM; Demoulin JB; Castaño JP; Öberg K; Giandomenico V
    PLoS One; 2012; 7(10):e48411. PubMed ID: 23119007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
    Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours.
    Laskaratos FM; Walker M; Naik K; Maragkoudakis E; Oikonomopoulos N; Grant L; Meyer T; Caplin M; Toumpanakis C
    Br J Cancer; 2016 Nov; 115(11):1321-1327. PubMed ID: 27811856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation.
    Pöll F; Lehmann D; Illing S; Ginj M; Jacobs S; Lupp A; Stumm R; Schulz S
    Mol Endocrinol; 2010 Feb; 24(2):436-46. PubMed ID: 20051480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
    Bousquet C; Lasfargues C; Chalabi M; Billah SM; Susini C; Vezzosi D; Caron P; Pyronnet S
    J Clin Endocrinol Metab; 2012 Mar; 97(3):727-37. PubMed ID: 22170729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary.
    Nolan LA; Schmid HA; Levy A
    Endocrinology; 2007 Jun; 148(6):2821-7. PubMed ID: 17347306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors.
    Kölby L; Wängberg B; Ahlman H; Tisell LE; Fjälling M; Forssell-Aronsson E; Nilsson O
    World J Surg; 1998 Jul; 22(7):679-83. PubMed ID: 9606281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE.
    Tadman M; Charlton P; Jafar-Mohammadi B; Talbot D; Grossman AB
    Endocr Pract; 2018 Feb; 24(2):189-194. PubMed ID: 29466059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted paclitaxel-octreotide conjugates inhibited the growth of paclitaxel-resistant human non-small cell lung cancer A549 cells in vitro.
    Liu Y; Xia H; Wang Y; Han W; Qin J; Gao W; Qu X; Wang X
    Thorac Cancer; 2021 Nov; 12(22):3053-3061. PubMed ID: 34617400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
    Janson ET; Oberg K
    Cancer Chemother Biol Response Modif; 2003; 21():535-46. PubMed ID: 15338762
    [No Abstract]   [Full Text] [Related]  

  • 36. Antitumor effects of somatostatin analogs in neuroendocrine tumors.
    Sidéris L; Dubé P; Rinke A
    Oncologist; 2012; 17(6):747-55. PubMed ID: 22628056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
    Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
    Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatostatin analogues inhibit cancer cell proliferation in an SSTR2-dependent manner via both cytostatic and cytotoxic pathways.
    Zou Y; Xiao X; Li Y; Zhou T
    Oncol Rep; 2009 Feb; 21(2):379-86. PubMed ID: 19148511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats.
    Tarasco E; Seebeck P; Pfundstein S; Daly AF; Eugster PJ; Harris AG; Grouzmann E; Lutz TA; Boyle CN
    Endocrine; 2017 Oct; 58(1):124-133. PubMed ID: 28822091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors.
    Feelders RA; de Herder WW; Neggers SJ; van der Lely AJ; Hofland LJ
    Drugs Today (Barc); 2013 Feb; 49(2):89-103. PubMed ID: 23462624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.